Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy-Reference-Cited by-同舟云学术

Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy

Published:2016-04-27 Issue:1 Volume:119 Page:30-37
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Heck Matthias M.¹,Thaler Markus A.²,Schmid Sebastian C.¹,Seitz Anna-Katharina¹,Tauber Robert¹,Kübler Hubert¹,Maurer Tobias¹,Thalgott Mark¹,Hatzichristodoulou Georgios¹,Höppner Michael¹,Nawroth Roman¹,Luppa Peter B.²,Gschwend Jürgen E.¹,Retz Margitta¹

Affiliation:

1. Department of Urology; Klinikum rechts der Isar; Technical University of Munich; Munich Germany

2. Institute of Clinical Chemistry and Pathobiochemistry; Klinikum rechts der Isar; Technical University of Munich; Munich Germany

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13493/fullpdf

Reference23 articles.

1. New therapies for castration-resistant prostate cancer;Longo;N Engl J Med,2010

2. Abiraterone and increased survival in metastatic prostate cancer;Bono;N Engl J Med,2011